950 related articles for article (PubMed ID: 28368383)
1. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
West NR; Hegazy AN; Owens BMJ; Bullers SJ; Linggi B; Buonocore S; Coccia M; Görtz D; This S; Stockenhuber K; Pott J; Friedrich M; Ryzhakov G; Baribaud F; Brodmerkel C; Cieluch C; Rahman N; Müller-Newen G; Owens RJ; Kühl AA; Maloy KJ; Plevy SE; ; Keshav S; Travis SPL; Powrie F
Nat Med; 2017 May; 23(5):579-589. PubMed ID: 28368383
[TBL] [Abstract][Full Text] [Related]
2. Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort.
Ezirike Ladipo J; He Z; Chikwava K; Robbins K; Beri J; Molle-Rios Z
J Pediatr Gastroenterol Nutr; 2021 Sep; 73(3):352-357. PubMed ID: 34117193
[TBL] [Abstract][Full Text] [Related]
3. Feiyangchangweiyan capsule protects against ulcerative colitis in mice by modulating the OSM/OSMR pathway and improving gut microbiota.
Li Y; Chen F; Xie Y; Yang Q; Luo H; Jia P; Shi Z; Wang S; Zheng X
Phytomedicine; 2021 Jan; 80():153372. PubMed ID: 33113505
[TBL] [Abstract][Full Text] [Related]
4. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.
Guo A; Ross C; Chande N; Gregor J; Ponich T; Khanna R; Sey M; Beaton M; Yan B; Kim RB; Wilson A
Sci Rep; 2022 Jan; 12(1):1185. PubMed ID: 35075155
[TBL] [Abstract][Full Text] [Related]
5. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.
Verstockt S; Verstockt B; Machiels K; Vancamelbeke M; Ferrante M; Cleynen I; De Hertogh G; Vermeire S
Inflamm Bowel Dis; 2021 Oct; 27(10):1564-1575. PubMed ID: 33624092
[TBL] [Abstract][Full Text] [Related]
6. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
7. Oncostatin M pathway plays a major role in the renal acute phase response.
Luyckx VA; Cairo LV; Compston CA; Phan WL; Mueller TF
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F875-83. PubMed ID: 19158344
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
[TBL] [Abstract][Full Text] [Related]
9. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
[TBL] [Abstract][Full Text] [Related]
10. Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans.
Keulen DV; Pouwer MG; Emilsson V; Matic LP; Pieterman EJ; Hedin U; Gudnason V; Jennings LL; Holmstrøm K; Nielsen BS; Pasterkamp G; Lindeman JHN; van Gool AJ; Sollewijn Gelpke MD; Princen HMG; Tempel D
PLoS One; 2019; 14(8):e0221477. PubMed ID: 31461490
[TBL] [Abstract][Full Text] [Related]
11. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.
Chen D; Chu CY; Chen CY; Yang HC; Chiang YY; Lin TY; Chiang IP; Chuang DY; Yu CC; Chow KC
J Pathol; 2008 Jul; 215(3):290-9. PubMed ID: 18491353
[TBL] [Abstract][Full Text] [Related]
12. Loss of Oncostatin M Signaling in Adipocytes Induces Insulin Resistance and Adipose Tissue Inflammation in Vivo.
Elks CM; Zhao P; Grant RW; Hang H; Bailey JL; Burk DH; McNulty MA; Mynatt RL; Stephens JM
J Biol Chem; 2016 Aug; 291(33):17066-76. PubMed ID: 27325693
[TBL] [Abstract][Full Text] [Related]
13. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract][Full Text] [Related]
14. Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab.
Bertani L; Fornai M; Fornili M; Antonioli L; Benvenuti L; Tapete G; Baiano Svizzero G; Ceccarelli L; Mumolo MG; Baglietto L; de Bortoli N; Bellini M; Marchi S; Costa F; Blandizzi C
Aliment Pharmacol Ther; 2020 Jul; 52(2):284-291. PubMed ID: 32506635
[TBL] [Abstract][Full Text] [Related]
15. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
16.
Tan B; Luo W; Shen Z; Xiao M; Wu S; Meng X; Wu X; Yang Z; Tian L; Wang X
Scand J Gastroenterol; 2019 Apr; 54(4):432-440. PubMed ID: 30946611
[No Abstract] [Full Text] [Related]
17. Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts.
Kokkotis G; Filidou E; Tarapatzi G; Spathakis M; Kandilogiannakis L; Dovrolis N; Arvanitidis K; Drygiannakis I; Valatas V; Vradelis S; Manolopoulos VG; Paspaliaris V; Kolios G; Bamias G
Inflamm Bowel Dis; 2024 May; ():. PubMed ID: 38717842
[TBL] [Abstract][Full Text] [Related]
18. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members.
Beigel F; Friedrich M; Probst C; Sotlar K; Göke B; Diegelmann J; Brand S
PLoS One; 2014; 9(4):e93498. PubMed ID: 24710357
[TBL] [Abstract][Full Text] [Related]
19. Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab.
Bertani L; Barberio B; Fornili M; Antonioli L; Zanzi F; Casadei C; Benvenuti L; Facchin S; D'Antongiovanni V; Lorenzon G; Ceccarelli L; Baglietto L; de Bortoli N; Bellini M; Costa F; Savarino EV; Fornai M
Dig Liver Dis; 2022 Oct; 54(10):1367-1373. PubMed ID: 35393259
[TBL] [Abstract][Full Text] [Related]
20. Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.
Yoon SM; Haritunians T; Chhina S; Liu Z; Yang S; Landers C; Li D; Ye BD; Shih D; Vasiliauskas EA; Ippoliti A; Rabizadeh S; Targan SR; Melmed GY; McGovern DPB
Inflamm Bowel Dis; 2017 Aug; 23(8):1382-1393. PubMed ID: 28590340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]